TrialDiabetes, obesity & metabolism2022

Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.

Monika Kellerer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.